- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Colorectal cancer
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1296KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 147KB)
Regorafenib – November 2021
Regorafenib: Tablet 40 mg (as monohydrate); Stivarga®
Last updated
4 March 2022